Datwyler injects CHF 100m into US drug delivery component site

By Staff Reporter

- Last updated on GMT

Image: iStock/Dzmitry Siarou
Image: iStock/Dzmitry Siarou

Related tags Injection Pharmacology Pharmaceutical drug

Increasing demand for reduced particle loads in pharmaceutical containers has driven Datwyler to build a CHF 100m plant making elastomer components for injectable drug delivery systems.

The Altdorf, Switzerland-based component manufacturer announced it was targeting the US market through the CHF 100m ($103m) investment last month, and the Delaware-located plant is expected to provide around 120 jobs once fully operational.

According to Megan Williamson, VP of Injection Systems at Datwyler​, the firm already produces around 15 billion components for vials, bottles, prefilled syringes and cartridges for pharmaceutical use per year, but the new ‘FirstLine’ facility will cater to industry's changing demands for injectable drug delivery systems.

“There is an increasing demand for reduced particle loads in pharmaceutical containers. As a result, the requirements and expectations of vial, syringe, and cartridge components are changing,”​ she told in-Pharmatechnologist.com.  

“For coated elastomeric closures, barrier properties alone are no longer enough to meet the needs of biologic drugs. In the conservative, data-driven industry of parenteral packaging, market trends indicate a growing demand for fluoropolymer coated elastomeric closures, primarily to mitigate risks related to drug stability and compatibility.”

Datwyler has operated a pharma packaging components facility in New Jersey since 1981, but this latest project will substantially increase the firm’s presence in the US.

“The new FirstLine plant is being built to serve the fast-growing and constantly evolving North American market,”​ she continued. “The opportunities in this market, and in Datwyler’s pipeline, support the need for high-quality components, ideally sourced from a local production facility.”

Construction is to begin before the end of the year and Datwyler expects the site to be operational by the first half of 2018.

Related news

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us